Delisted
Humanigen's stock was delisted from Nasdaq on October 12, 2023.
The business overview below summarizes the 10-K filed March 30, 2023, which predates these events.
Sources: 25-NSE (Oct 12, 2023)
Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company headquartered in Short Hills, NJ, incorporated in Delaware, and listed on Nasdaq. The company develops proprietary "Humaneered" monoclonal antibodies — engineered high-affinity human antibodies converted from murine precursors — targeting inflammatory, immunological, and oncological conditions.
Core Technology Humanigen's proprietary Humaneered technology platform converts existing (typically murine) antibodies into engineered, high-affinity human antibodies. Humaneered antibodies are designed to offer high potency, slow off-rate, and a lower likelihood of inducing immune responses compared to chimeric or conventionally humanized antibodies.
Lead Product: Lenzilumab (LENZ) Lenzilumab is a Humaneered monoclonal antibody that neutralizes human GM-CSF (granulocyte-macrophage colony-stimulating factor), a cytokine linked to monocyte overproduction and inflammatory pathology. Humanigen is pursuing lenzilumab across three indications:
- Chronic Myelomonocytic Leukemia (CMML): A rare blood cancer with ~1,700 new US/UK/Australia cases annually and a 20-month median overall survival. In a Mayo Clinic Phase 1 study, 3 of 6 patients...
AI-generated summary of Item 1 (Business) from the 10-K filed Mar 30, 2023 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Annual results · 10-K
Fiscal 2022- Revenue
- $2.5M
- Net loss
- -$70.7M
As reported in the fiscal 2022 annual report.